Indications and uses
First Aid to help protect against infection in minor cuts scrapes burns
First Aid to help protect against infection in minor cuts scrapes burns
clean the affected area shake can well before using hold can 4 to 6 inches away from injury and spray area until wet for adult institutional use only not intended for use on children
Benzethonium Chloride 0.2% w/w
Benzocaine 3.2% w/w
Topical Antiseptic
Topical Anesthetic
First Aid to help protect against infection in
minor cuts
scrapes
burns
For external use only
Flammable
keep away from fire or flame
contents under pressure
do not puncture or incinerate container
do not expose to temperatures above 120°(F)
in or near the eyes or other mucous membranes
in case of serious burn
in deep puncture wounds
for prolonged period of time
on large portions of the body
if redness, swelling, or irritation occurs
infection occurs
condition persists or worsens
symptoms persist for more than 7 days
If swallowed, get medical help or contact a Poison Control Center right away.
clean the affected area
shake can well before using
hold can 4 to 6 inches away from injury and spray area until wet
for adult institutional use only
not intended for use on children
avoid inhaling
use only as directed
intentional misuse by deliberately concentrating and inhaling the contents may be harmful or fatal
Ethyl Alcohol, PVP-VA Copolymer, N-Butane, Propane, Isobutane
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 52982-105-03 | 2023-01-19 | C162847 | 48780-1 | 9855d018-ebd9-cd31-e053-dbdaa90ab51a | YOUR LOGO HERE BANDAGE SPRAY |
| 52982-105-03 | 2023-01-19 | C162847 | 48780-1 | 9855d018-ebd9-cd31-e053-dbdaa90ab51a | YOUR LOGO HERE BANDAGE SPRAY |
| 52982-105-03 | 2019-11-27 | C162847 | 48780-1 | 9855d018-ebd9-cd31-e053-dbdaa90ab51a | YOUR LOGO HERE BANDAGE SPRAY |
| 52982-105-03 | 2019-11-27 | C162847 | 48780-1 | 9855d018-ebd9-cd31-e053-dbdaa90ab51a | YOUR LOGO HERE BANDAGE SPRAY |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BENZETHONIUM CHLORIDE | ACTIVE INGREDIENT | PH41D05744 | 1 | |
| BENZOCAINE | ACTIVE INGREDIENT | U3RSY48JW5 | 1 | |
| BENZETHONIUM | ACTIVE MOIETY | 1VU15B70BP | 1 | |
| BENZOCAINE | ACTIVE MOIETY | U3RSY48JW5 | 1 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 1 | |
| BUTANE | INACTIVE INGREDIENT | 6LV4FOR43R | 1 | |
| COPOVIDONE K25-31 | INACTIVE INGREDIENT | D9C330MD8B | 1 | |
| ISOBUTANE | INACTIVE INGREDIENT | BXR49TP611 | 1 | |
| PROPANE | INACTIVE INGREDIENT | T75W9911L6 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 52982-105 | 52982-105-03 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| BENZOCAINE | U3RSY48JW5 | ACTIB |
| BENZETHONIUM CHLORIDE | PH41D05744 | ACTIB |
| COPOVIDONE K25-31 | D9C330MD8B | IACT |
| ALCOHOL | 3K9958V90M | IACT |
| BUTANE | 6LV4FOR43R | IACT |
| PROPANE | T75W9911L6 | IACT |
| ISOBUTANE | BXR49TP611 | IACT |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 5 | 2025-01-28 | full-release | 2026-06-01 00:53:58 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | SUSPENSION / ORAL | 172 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE / ORAL | 1346 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, DELAYED RELEASE / ORAL | 168 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE / ORAL | 1346 mg | ||
| PROPANE | PROPANE | T75W9911L6 | AEROSOL, FOAM / TOPICAL | 55 %w/w | ||
| BUTANE | BUTANE | 6LV4FOR43R | AEROSOL / TOPICAL | NA | ||
| ISOBUTANE | ISOBUTANE | BXR49TP611 | AEROSOL, SPRAY / TOPICAL | 4484 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | SUSPENSION / ORAL | 172 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 53 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | POWDER, FOR SUSPENSION / ORAL | 5917 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, FILM COATED / ORAL | 5917 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE, COATED PELLETS / ORAL | 88 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, EXTENDED RELEASE / ORAL | 300 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE, EXTENDED RELEASE / ORAL | 200 mg | ||
| BUTANE | BUTANE | 6LV4FOR43R | AEROSOL, FOAM / TOPICAL | 27 %w/w | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, CHEWABLE / ORAL | 5 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET / SUBLINGUAL | 54 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, ORALLY DISINTEGRATING / ORAL | 35 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE, DELAYED RELEASE / ORAL | 199 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| PROPANE | PROPANE | T75W9911L6 | AEROSOL, FOAM / TOPICAL | 55 %w/w | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 53 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | PELLET / ORAL | 1653 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE, DELAYED RELEASE / ORAL | 199 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE, EXTENDED RELEASE / ORAL | 200 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, ORALLY DISINTEGRATING / ORAL | 35 mg | ||
| BUTANE | BUTANE | 6LV4FOR43R | AEROSOL, FOAM / TOPICAL | 27 %w/w | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET / ORAL | 6374 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | PELLET / ORAL | 1653 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET / SUBLINGUAL | 54 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, EXTENDED RELEASE / ORAL | 300 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET / ORAL | 6374 mg | ||
| ISOBUTANE | ISOBUTANE | BXR49TP611 | AEROSOL, SPRAY / TOPICAL | 4484 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, FILM COATED / ORAL | 5917 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, DELAYED RELEASE / ORAL | 168 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | POWDER, FOR SUSPENSION / ORAL | 5917 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | CAPSULE, COATED PELLETS / ORAL | 88 mg | ||
| BUTANE | BUTANE | 6LV4FOR43R | AEROSOL / TOPICAL | NA | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, CHEWABLE / ORAL | 5 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Your Logo Here Bandage Aid | BENZETHONIUM CHLORIDE AND BENZOCAINE | Dixon Investments, Inc. | b2fdd15e-8305-4c0d-9475-c3a1b49a79a1 | 2025-01-28 | Warnings | 52982-105-03 52982-105 52982010503 b2fdd15e-8305-4c0d-9475-c3a1b49a79a1 |
Adverse event summaries are temporarily unavailable. Other product information remains available.